Protalix BioTherapeutics(PLX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - As of December 31, 2025, the company held $30.3 million in cash equivalents and short-term bank deposits, with a projected cash balance of approximately $50 million by early April 2026 [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [11] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [11] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [5] - The approval of the every four weeks regimen in Europe is expected to significantly enhance Elfabrio's market uptake [5] Company Strategy and Development Direction - The company aims to advance its clinical pipeline, including PRX-115 and PRX-119, while maintaining a strong financial position to support these initiatives [12] - The company is focused on expanding its renal pipeline and expects to provide updates on specific indications and mechanisms of action in the coming months [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial flexibility and growth trajectory, projecting revenue growth in 2026 of greater than 50% [12] - The approval of the every four weeks regimen in Europe is seen as a significant competitive edge, with expectations for accelerated approval in the U.S. [17] Other Important Information - The company anticipates top-line results from the PRX-115 RELEASE study in the second half of 2027 [6] - The company is expanding its renal pipeline through collaborations and new candidates [7] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. and sales trajectory in Europe - Management highlighted ongoing promotional activities by Chiesi, including patient ambassador programs, and noted that the approval of the four-week regimen in Europe is expected to enhance market positioning [16] Question: Positioning of PRX-115 in the gout market - Management discussed the potential competitive advantages of PRX-115, including dosing frequency and safety, and projected a significant market opportunity for uncontrolled gout [18][20] Question: Target indications for PRX-119 and potential commercial opportunities - Management indicated that they are targeting high unmet need renal indications and will provide updates on specific mechanisms of action in the future [22][23] Question: Timeline for rollout of Elfabrio's four-week dosing in Europe - Management stated that availability will vary by country, with expectations for rollout starting in the second half of 2026 [27][30] Question: Physician education efforts accompanying the rollout - Management confirmed that Chiesi is actively engaging with treating physicians and stakeholders to promote the new regimen [31]